Additionally, the ORIENT-31 trial demonstrated that treatment with the PD-1 inhibitor sintilimab, bevacizumab biosimilar IBI305, and standard chemotherapy (pemetrexed and cisplatin) significantly improved PFS compared to chemotherapy alone (median 7.2 months vs 4.3 months; hazard ratio 0.51; p<0.0001) for NSCLC patients who had progressed after EGFR TKI therapy (11). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.